FDA Class II Recall: Consumer Product Partners' White Petrolatum Labeling Mix-Up Impacts Major Retailers
Consumer Product Partners, LLC initiated a Class II recall for 1,015 cases of White Petrolatum USP due to a critical labeling mix-up. Products, sold under Rite Aid, Kroger, Harris Teeter, and CVS brands, were mislabeled as 'pure' but contained lavender and chamomile. This event underscores significant supply chain and regulatory risks for procurement and quality assurance teams.
FDA Class II Recall: Labeling Discrepancy for White Petrolatum USP
Consumer Product Partners, LLC has initiated a voluntary Class II recall, designated D-0560-2024, for 1,015 cases of its Petroleum Jelly, White Petrolatum USP. The recall, initiated on May 28, 2024, and terminated on August 21, 2025, stems from a critical labeling mix-up: products marked as 'pure white petroleum jelly' actually contained a formulation with lavender and chamomile. This discrepancy affects a single lot, #0607983, with an expiration date of July 2026. The recalled product was distributed nationwide across the United States, impacting major retail pharmacy chains. Specifically, the affected products include Rite Aid brand (NDC #11822-3135-2, UPC 0-11822-51349-4), Kroger brand (NDC #30142-069-27, UPC 0-41260-35275-1), Harris Teeter brand (NDC #72036-069-27, UPC 0-72036-75051-8), and CVS brand (NDC #59779-069-27, UPC 0-50428-31702-0). For procurement directors, this event highlights the imperative of stringent quality control and verification protocols for all incoming raw materials and finished goods, particularly for private label products where brand reputation is directly tied to supplier compliance. Regulatory affairs heads must ensure that supplier audit programs are robust enough to detect such critical deviations in labeling and formulation, which can lead to significant market disruption and potential consumer health risks.
Supply Chain Vulnerabilities: Impact on Major Retailers
The nationwide distribution of 1,015 cases of mislabeled White Petrolatum USP by Consumer Product Partners, LLC from its Smyrna, TN location exposes significant vulnerabilities within the supply chains of prominent retailers like Rite Aid, The Kroger Co., Harris Teeter, and CVS Pharmacy, Inc. These companies rely on contract manufacturers for their private label offerings, making them directly susceptible to supplier quality failures. The recall of a foundational OTC drug like petrolatum, a common emollient, can disrupt shelf availability and erode consumer confidence in store brands. Supply chain VPs must recognize that a single labeling error at a contract manufacturer can trigger a costly, widespread recall impacting multiple retail partners simultaneously. The logistical burden of identifying, retrieving, and replacing 1,015 cases across a national footprint is substantial, incurring significant operational costs and potential lost sales. Furthermore, the incident underscores the need for robust traceability systems that can pinpoint affected batches rapidly, minimizing the scope and duration of recalls. Business development executives should consider the long-term brand damage and the potential for consumers to shift loyalty to national brands perceived as more reliable, especially for essential personal care items. This event serves as a critical reminder that supplier due diligence and continuous monitoring are paramount to safeguarding both product integrity and brand equity in competitive retail environments.
Product Integrity and Consumer Trust Implications
The core issue of this recall—a product labeled as 'pure white petroleum jelly' containing added fragrances like lavender and chamomile—carries significant implications for product integrity and consumer trust. While white petrolatum (UNII: 4T6H12BN9U) is a widely used, inert emollient, the inclusion of additional ingredients without proper disclosure can pose risks, particularly for sensitive populations. Consumers seeking 'pure' petrolatum, often for hypoallergenic purposes or for infants, could experience adverse reactions to undisclosed fragrances. This mislabeling directly violates consumer expectations and regulatory requirements for accurate product information. For regulatory affairs heads, this highlights the critical importance of ingredient transparency and allergen labeling, even for seemingly innocuous additions. The Class II classification by the FDA indicates that while the probability of serious adverse health consequences is remote, temporary or medically reversible adverse health consequences are possible. Business development executives must consider how such incidents can tarnish brand reputation, especially for private label products where trust is built on consistency and reliability. Rebuilding consumer trust after a labeling error requires transparent communication and demonstrable corrective actions, emphasizing the rigorous quality controls now in place to prevent recurrence. This incident underscores that even minor deviations from declared formulations can have far-reaching commercial and reputational consequences.
Strategic Sourcing for Petrolatum: Mitigating Future Risks
For procurement directors and supply chain VPs, the Consumer Product Partners, LLC recall serves as a stark reminder of the necessity for strategic sourcing and supplier diversification for critical excipients like petrolatum. While the specific manufacturing facility details beyond the recalling firm's Smyrna, TN address are not available, the event highlights the risks associated with relying on a single source or a limited pool of contract manufacturers for private label formulations. To mitigate future risks, procurement teams should proactively identify and qualify alternative suppliers of White Petrolatum USP. This involves rigorous auditing processes that extend beyond financial stability to include comprehensive assessments of quality management systems, manufacturing controls, and labeling accuracy protocols. Geographic diversity among suppliers can also reduce exposure to localized disruptions. Qualification timelines for new suppliers, especially for pharmaceutical-grade ingredients, can be extensive, often spanning 12-18 months, necessitating a proactive approach to supplier mapping and redundancy planning. Furthermore, establishing clear, legally binding quality agreements with all contract manufacturers, specifying responsibilities for labeling, change control, and recall procedures, is essential. This proactive approach ensures business continuity and protects against the commercial and reputational fallout from supplier non-compliance, safeguarding the integrity of the entire supply chain.
Post-Recall Compliance and Market Repercussions
The termination of recall D-0560-2024 on August 21, 2025, indicates that Consumer Product Partners, LLC has completed the necessary actions to remove the mislabeled White Petrolatum USP from the market. However, the regulatory scrutiny does not necessarily end with recall termination. The FDA will monitor the firm's corrective and preventive actions (CAPA) to ensure the root cause of the labeling mix-up has been thoroughly addressed and controls are implemented to prevent recurrence. For regulatory affairs heads, this means ongoing engagement with the FDA and a demonstrable commitment to compliance. While no prior regulatory actions against Consumer Product Partners, LLC are detailed in the available knowledge graph, this recall will be part of their compliance record. The market repercussions extend beyond the immediate financial costs of the recall. Retailers like Rite Aid, Kroger, Harris Teeter, and CVS Pharmacy, Inc. must now reinforce their own quality assurance programs for private label products, potentially increasing their oversight of contract manufacturers. Business development executives should anticipate heightened scrutiny from retail partners regarding quality certifications and audit results. This event underscores that even for seemingly low-risk, over-the-counter products, a lapse in quality control can trigger significant regulatory action, erode consumer trust, and necessitate substantial operational and reputational recovery efforts.